skip to Main Content

Questions Remain in Localized Pancreatic Cancer as More Treatment Modalities Emerge

Questions Remain in Localized Pancreatic Cancer as More Treatment Modalities Emerge
Findings from 3 key trials have shed light on how to approach neoadjuvant and adjuvant treatment for patients with pancreatic cancer, according to Pablo Ferraro, MD, but pivotal questions regarding disease biology and the potential role of emerging modalities in the paradigm have yet to be answered.

In the neoadjuvant setting, data from the phase III PREOPANC-1 trial showed that the combination of preoperative chemotherapy and radiation led to a better survival benefit in patients with resectable or borderline resectable disease compared with immediate surgery.  Read more . . .  


Back To Top